Skip to content
Menu

Elicio Therapeutics, Inc. ELTX

Full chart Compare
Set alert

Price alert · ELTX

All alert types
1.45 USD -0.05 (-3.33%)

Regular-session close

1.45 0.00 0.00%

After hours · Nov 20, 7:30 PM ET

1.44 Day range 1.59
1.40 52-week range 14.85
YTD
-81.78%
1 year
-81.85%

5D -0.03 (-2.03%)

1.401.501.60MonTueWedThuFri1.45
Market cap
41.05M
EPS (ttm)
-1.81
Shares out
10.79M
Forward P/E
-1.96
YTD return
-81.78%
1-year return
-81.85%
50-day average
4.92
200-day average
5.97
Volume
231.65K
Avg volume
325.45K
Open
1.47
Previous close
1.50
Day's range
1.44 – 1.59
52-week range
1.40 – 14.85
Analysts
Buy
Price target
9.50 (+555.2%)

Key statistics

Enterprise value
61.64M
Price / book
4.25
Free cash flow
-22.08M
Total cash
3.42M
Total debt
6.42M
Return on equity
-353.02%
Short % of float
0.49%

Fundamental scorecard

5 of 25 checks passed on ELTX’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ELTX Revenue — quarterly 0
ELTX Net income — quarterly -7.98M
ELTX EPS — quarterly -0.30

Earnings

ELTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 2024-0.81-1.39-0.58-71.60%
Aug 13, 2024Jun 1, 2024-0.96-0.64+0.32+33.33%
Aug 13, 2024Jun 1, 2024-0.96———
May 15, 2024Mar 1, 2024-1.09———
May 15, 2024Mar 1, 2024-1.09-1.15-0.06-5.50%
Mar 29, 2024Dec 1, 2023-0.79———

Upgrades / downgrades

ELTX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 31, 2024Jones Tradinginit—Buy
Aug 23, 2024HC Wainwright & Co.reitBuyBuy
Jun 6, 2024HC Wainwright & Co.reitBuyBuy
May 22, 2024HC Wainwright & Co.reitBuyBuy
May 1, 2024HC Wainwright & Co.mainBuyBuy
Apr 1, 2024OppenheimerreitPerformPerform

About Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node–targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
elicio.com

News

Your note

Sign in to keep a note on ELTX — it syncs with the Stock Master app.

Insider holders

ELTX insider holders
InsiderRelationLatest transactionDateShares held
CHUDNOVSKY YEKATERINADirector and Beneficial Owner of more than 10% of a Class of SecurityPurchaseDec 21, 20230
DEMUTH PETEROfficerConversion of Exercise of derivative securityDec 15, 2024381
VENKATESAN JAY RDirectorConversion of Exercise of derivative securityNov 25, 2024180,534

Institution ownership

ELTX institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc2.27%245,2621.23MSep 29, 2024
Geode Capital Management, LLC0.66%71,574360.02KSep 29, 2024
CM Management, LLC0.46%50,000251.50KSep 29, 2024
Northern Trust Corporation0.29%30,769154.77KSep 29, 2024
State Street Corporation0.20%21,900110.16KSep 29, 2024
Blackrock Inc.0.18%19,69399.06KSep 29, 2024

Fund ownership

ELTX fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.89%203,4761.02MSep 29, 2024
Vanguard Extended Market Index Fund0.38%41,473208.61KSep 29, 2024
Fidelity Extended Market Index Fund0.32%34,422173.14KOct 30, 2024
iShares Micro Cap ETF0.16%17,07885.90KOct 30, 2024
Northern Small Cap Core Fund0.12%13,00065.39KSep 29, 2024
Bridgeway Funds Inc-Ultra Small Company Market Fund0.12%12,50062.88KSep 29, 2024